Advaxis completes ADXS-HPV Stage 1/2 dosing in patients with HPV-associated anal cancer Advaxis.

It also provides valuable insight into the combination of ADXS-HPV with concurrent radiation and chemotherapy, commented Dr. Robert Petit, VP of Clinical Procedures and Medical Affairs at Advaxis.. Advaxis completes ADXS-HPV Stage 1/2 dosing in patients with HPV-associated anal cancer Advaxis, Inc., , a head in developing the next generation of immunotherapies for malignancy and infectious diseases, announced that the 1st patient offers been dosed in a Stage 1/2 study of ADXS-HPV in 25 patients with HPV-linked anal cancers coordinated by the Dark brown University Oncology Analysis Group .The fast-moving bloodstream contamination is considered the priciest in-hospital condition, costing more than $20 billion every year in the U.S.5 billion in the united kingdom. Abbott has developed a platform predicated on PCR/ESI-MS technology with the goal to deliver a wide range of assessments that can identify hundreds of bacteria, fungi and infections from a patient specimen within eight hours directly. The platform, known as IRIDICA , is expected to be accessible as a CE marked in vitro diagnostic device in European countries within the coming months.

ASTRO accepts 4 abstracts on Stereotactic Body Radiation Therapy for NSCLC The American Society for Radiation Oncology has accepted four abstracts from users of Elekta Stereotactic Body Radiation Therapy technology on the use of SBRT to take care of non-small cell lung cancer .

-->